Proactive - Interviews for investors

Sintana Energy CEO Robert Bose recently spoke with Steve Darling from Proactive to provide an update on the company’s second exploration campaign in Namibia’s Orange Basin. The campaign is focused on Blocks 2813A and 2814B, governed by Petroleum Exploration License 83 (PEL 83), which is operated by Galp Energia. Sintana indirectly holds a 49% interest in Custos Energy, which maintains a 10% working interest in PEL 83, alongside NAMCOR’s 10% stake.

The PEL 83 Joint Venture recently announced a significant milestone: the successful drilling and logging of the Mopane-2A well (Well #4), which spud on December 2. The exploration revealed hydrocarbons in two reservoirs: a gas-condensate column in AVO-3, characterized by thin net pay within its sweet spot, and a light oil column in AVO-4.

Bose highlighted the reservoirs' promising characteristics, including high-quality sands with excellent porosity, permeability, pressure, and fluid properties. Additionally, the reservoirs exhibited minimal CO2 content and no H2S or water contacts, further underscoring their quality.

The data collected from Mopane-2A is now under analysis to deepen the understanding of the Mopane complex and evaluate its commercial viability. Meanwhile, the drillship has relocated to the Mopane-3X exploration well (Well #5) site, where drilling is set to target two stacked prospects, AVO-10 and AVO-13. Spudding for this well is scheduled for early January.

This progress reflects Sintana Energy’s commitment to advancing its exploration initiatives in one of the world’s most promising emerging hydrocarbon basins.

#proactiveinvestors #sintanaenergyinc #tsxv #sei #otcqb #seusf #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews #OilExploration #Namibia #OrangeBasin #EnergySector #PEL83 #RobertBose #GalpEnergia #Chevron #QatarEnergy #EnergyNews #ProactiveInvestors #2025EnergyTrends

#investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson talked with Proactive's Stephen Gunnion about the company's acquisition of NexusBio Ag assets from Univar Solutions Canada Ltd. Giasson emphasized the significance of this deal, highlighting how it transitions MustGrow from a pre-revenue company to one with substantial revenues. The acquisition includes an established sales team, a marketing division, and a range of synergistic products, including biologics and bio-stimulants, sold in the Canadian agricultural market.

“This acquisition is a turning point for us,” Giasson explained, noting that the deal brings immediate access to a strong distribution network and existing market relationships. He also discussed plans to leverage these assets for cost synergies, expand sales into the US, and grow its proprietary product portfolio in collaboration with Bayer.

Giasson outlined the terms of the acquisition, which includes $1.60 million in deferred payments for inventory and equipment, with additional success fees scheduled for 2025 and 2026. The CEO expressed optimism for 2025 as MustGrow integrates the NexusBio division and advances its global partnerships.

Visit Proactive's YouTube channel for more videos, and don't forget to like, subscribe, and turn on notifications to stay updated on future content!

#MustGrowBiologics #NexusBioAg #AgricultureInnovation #Biologics #RegenerativeAgriculture #FarmingTechnology #SustainableFarming #CropScience #Agriculture2025 #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

HIVE Digital Technologies Ltd executive chairman Frank Holmes talked with Proactive's Stephen Gunnion about the company’s remarkable achievements and future goals. Holmes shared how Hive ended 2024 by achieving a 6 Exahash per second (EH/s) milestone, a 47% increase from December 2023. This accomplishment was driven by upgrading to more energy-efficient machines, particularly the Avalon units from Canaan, improving Bitcoin mining efficiency and output.

He highlighted Hive's ability to secure competitive energy pricing in Sweden, locking in electricity costs below $0.02 per kilowatt-hour. Holmes also reflected on the team's global coordination across multiple languages and time zones, noting Hive's impressive revenue per employee—approximately $6 million, surpassing giants like Nvidia and Apple.

Looking ahead to 2025, Hive aims to reach 12-15 exahashes per second within six months, targeting around 2% of the global Bitcoin network hash rate. Holmes emphasized the company's ongoing focus on operational efficiency and increasing Bitcoin holdings.

For more insights into Hive Digital’s innovations and strategies, visit Proactive's YouTube channel for more interviews. Don’t forget to like, subscribe, and enable notifications to stay updated on the latest content.

#HiveDigital #BitcoinMining #FrankHolmes #CryptoMining #EnergyEfficiency #CanaanAvalon #BitcoinHalving #TechInnovation #ProactiveInvestors#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Hemogenyx Pharmaceuticals PLC CEO Dr Vladislav Sandler talked with Proactive's Stephen Gunnion about a significant milestone for the company: the opening of its first clinical trial site and the commencement of patient recruitment for its lead drug, HG-CT-1. This Phase 1 trial is designed to evaluate the safety profile of HG-CT-1, a CAR-T therapy aimed at treating relapsed and refractory acute myeloid leukaemia (AML) in adult patients.

Sandler highlighted the trial's objectives, which include assessing the therapy's efficacy based on AML-specific response criteria, overall survival, progression-free survival, and duration of response. He emphasised that this trial represents a major step forward in offering hope to patients with limited treatment options. The trial is being conducted at a top-tier cancer research institution in the United States.

Discussing future plans, Sandler revealed that the company intends to expand trials to include pediatric patients with AML and acute lymphoblastic leukaemia, as well as patients suffering from the rare blood disease BPDCN. These efforts underline Hemogenyx's commitment to revolutionizing treatments for these conditions.

Stay tuned for more updates on Proactive’s YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content.

#HemogenyxPharmaceuticals #CAR-TTherapy #AMLResearch #CancerTreatment #ClinicalTrials #BiotechNews #HealthcareInnovation #ProactiveUpdates #Phase1Trials #proactiveinvestors

Mosman Oil and Gas Ltd (AIM:MSMN) CEO Andy Carroll discusses the company’s strategic acquisition of an 82.5% stake in the Sagebrush helium project in Colorado with Proactive's Stephen Gunnion. Carroll highlighted the area’s strong geological potential and the significance of combining it with the adjacent Coyote Wash project in the prospective Four Corners area.

He explained that Sagebrush comes with existing production infrastructure and demonstrated helium potential. "We have done a full technical review, and this area stands out for its proven helium source and excellent sealing properties," Carroll noted.

The acquisition is set to be finalized in January, bolstering Mosman’s portfolio, which also includes the Vecta helium project in Colorado and projects in Australia. Carroll emphasised a carefully considered exploration approach, leveraging extensive seismic data to identify high-potential targets.

With a diverse range of projects, Mosman Oil and Gas is positioning itself as a key player in helium exploration and production.

Stay tuned to Proactive's YouTube channel for more updates, and don’t forget to like the video, subscribe to our channel, and enable notifications for the latest content.

#HeliumExploration #MosmanOil #EnergySector #HeliumProjects #ColoradoEnergy #OilAndGas #ProactiveInvestors #NaturalResources #SustainableEnergy#ProactiveInvestors#invest

#investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

U.S. Global Investors CEO Frank Holmes joined Steve Darling from Proactive to announce the launch of the company’s first actively managed exchange-traded fund , the U.S. Global Technology and Aerospace & Defence ETF, trading under the symbol "WAR" on the New York Stock Exchange.

This launch marks a significant milestone, building on the success of the company’s flagship U.S. Global Jets ETF, which has exceeded $1 billion in assets under management. The WAR ETF aims to capitalize on the increasing global demand for advanced defence and protection technologies, providing investors with exposure to sectors such as semiconductors, artificial intelligence, data centers, cybersecurity, aerospace, and electronic warfare.

Designed to address modern challenges and geopolitical risks, the WAR ETF applies a smart beta 2.0 investment strategy that integrates quantitative and fundamental analysis to identify opportunities for long-term growth while mitigating risk.

Holmes highlighted the growing urgency for defense-related investments, citing that global military expenditures reached a record-breaking $2.4 trillion in 2023, following nine consecutive years of growth. He emphasized that this trend is particularly evident in Europe, where EU member states collectively plan to spend €326 billion on aerospace and defence this year—an unprecedented 1.9% of the bloc's GDP.

With its innovative approach and focus on high-growth industries, the WAR ETF seeks to offer investors diversified exposure to the critical technologies shaping the future of global defense and security.

#proactiveinvestors #usglobalinvestorsinc #nasdaq #grow #etf #jets #travel #colombia #WARETF #DefenseSpending #Cybersecurity #Semiconductors #Aerospace #SmartBeta #ETFs #NYSE

#investment #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Fah Mai Holdings Group Inc UK head Jacob Carter talked with Proactive's Stephen Gunnion about the state of the whisky industry in 2024 and expectations for 2025.

Carter highlighted both the challenges and opportunities the sector has faced. He noted significant declines in Scotch whisky exports, with volumes falling by 10.20% during the first half of 2024 due to global economic pressures, inflation, and tariffs. Auction values also saw steep declines, with a 50% drop in fine and rare whisky prices year-over-year in Q2. Additionally, the luxury segment has been under pressure, especially for high-end bottles aged over 50 years.

Despite these challenges, Carter pointed out areas of growth, such as increased demand in emerging markets like India (up 17.30%) and Japan (up 13%). Resilient brands like Glenfarclas and Port Ellen have shown modest gains, and iconic labels like Macallan continue to hold their position despite market volatility. Looking ahead to 2025, Carter predicts sustained demand for rare whiskys, further diversification across whisky brands globally, and the rise of digital platforms leveraging blockchain and NFTs for authentication.

To new investors in 2025, Carter advised starting with research and understanding market trends, setting clear budgets, diversifying portfolios, and consulting industry experts. For more information, visit Fah Mai Holdings at fahmaiholdings.com.

Visit Proactive's YouTube channel for more videos, and don’t forget to like, subscribe, and enable notifications for future updates!

#WhiskeyInvestment #ScotchWhiskey #RareWhiskeys #FahMaiHoldings #JacobCarter #WhiskeyMarket #EmergingMarkets #LuxurySpirits #WhiskeyAuctions #InvestmentTips#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ananda Pharma Plc (AQSE:ANA) co-founder co-founder and CEO Melissa Sturgess talked with Proactive's Stephen Gunnion about the company’s evolution and progress in drug development. Sturgess shared the significance of the recent name change from Ananda Developments to Ananda Pharma, reflecting the company's focus on developing pharmaceutical-grade medicines.

She highlighted collaborations with key opinion leaders in areas like chemotherapy-induced pain, endometriosis, and refractory epilepsy. These partnerships have enabled the company to secure non-dilutive government funding for its two Phase 2 and two Phase 3 clinical trials, with patient dosing expected in 2025.

Additionally, Sturgess discussed the company’s recent £150,000 investment from new investors and a successful £2 million fundraising in September, backed by its chairman and largest shareholder. This financial support positions Ananda Pharma to advance its clinical trials and regulatory preparations for global markets.

Looking ahead to 2025, Sturgess described this as the most optimistic phase in Ananda Pharma’s journey.

For more updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content.

#AnandaPharma #MelissaSturgess #CannabisMedicine #ClinicalTrials #CannabinoidResearch #DrugDevelopment #Pharmaceuticals #InvestingInHealth #CBDMedicine #HealthcareInnovation#ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Georgina Energy PLC (LSE:GEX) CEO Anthony Hamilton talked with Proactive's Stephen Gunnion about the company’s progress at the Hussar and Mt Winter projects, as well as plans for 2025. Hamilton outlined the challenges faced during the Hussar project due to severe weather, which temporarily delayed personnel movement. Despite these setbacks, the company is confident about obtaining its drilling permit early next year.

For Mt Winter, Hamilton highlighted progress, including steps toward finalising an Aboriginal land access agreement and seismic data reprocessing. He noted, "The beauty of these assets is that they have proven concentrations of helium, hydrogen, and natural gas at surface."

Additionally, Hamilton discussed ongoing negotiations for farm-in agreements with major oil and gas companies and Georgina Energy’s strategic focus on upgrading resources through detailed studies and partnerships.

Looking ahead, the company is gearing up for key milestones in the first quarter of 2025, including scoping studies and announcements on farm-ins. Hamilton emphasised the company’s commitment to advancing its projects despite weather challenges and seasonal constraints.

For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and enable notifications for future updates.

#GeorginaEnergy #HussarProject #MtWinterProject #HeliumExploration #Hydrogen #NaturalGas #EnergyInnovation #ProactiveInvestors #OilAndGas #EnergyExploration#ProactiveInvestors#invest

#investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce an important milestone for the company’s New Drug Application (NDA) for a novel fibromyalgia treatment. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, marking the anticipated timeline for a decision on marketing approval.

The treatment is a non-opioid, centrally acting therapy designed to address fibromyalgia, a chronic and debilitating pain condition that disproportionately affects women and impacts over 10 million adults in the United States. Highlighting the significance of the FDA collaboration, Dr. Lederman stated, “We believe this therapy has the potential to become the first in a new class of medicines for managing fibromyalgia.” Data from pivotal Phase 3 trials demonstrated meaningful pain reduction with a favorable safety profile, addressing an urgent unmet need in the fibromyalgia patient community.

The NDA submission is supported by data from two 14-week, double-blind, randomized, placebo-controlled Phase 3 clinical trials, which confirmed the treatment's efficacy and tolerability with no new safety concerns. Previously granted Fast Track designation by the FDA in July 2024, the therapy is recognized for its potential to transform the fibromyalgia treatment landscape.

If approved, this innovative therapy would be the first new drug for fibromyalgia in more than 15 years, offering hope to millions of patients seeking effective and tolerable treatment options.

#proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp

#FibromyalgiaTreatment #FDAApproval #TNX102SL #NonOpiateTherapy #PharmaNews #DrugDevelopment #ProactiveInvestors#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews